Wikisage, the free encyclopedia of the second generation, is digital heritage
Zimeldine: Difference between revisions
Jump to navigation
Jump to search
(Created page with "While zilmelidine had a very favorable safety profile, within a year and a half of its introduction, rare case reports of Guillain–Barré syndrome emerged that appeared to b...") |
(→Links) |
||
Line 3: | Line 3: | ||
[https://karmel.miraheze.org/w/index.php?title=Zimeldina&oldid=8535 Karmel(miraheze)] | [https://karmel.miraheze.org/w/index.php?title=Zimeldina&oldid=8535 Karmel(miraheze)] | ||
{{Wikidata| | {{Wikidata|Q203483}} |
Revision as of 14:12, 21 March 2019
While zilmelidine had a very favorable safety profile, within a year and a half of its introduction, rare case reports of Guillain–Barré syndrome emerged that appeared to be caused by the drug, prompting its manufacturer to withdraw it from the market